{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T17:56:18Z","timestamp":1773338178069,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T00:00:00Z","timestamp":1601337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Immunoglobulin light chain (AL) amyloidosis is a rare, multi-systemic disorder characterized by two disease processes: an underlying plasma cell dyscrasia that provides the source of pathologic light chains, and the resulting organ dysfunction caused by deposition of amyloid light chain fibrils. There are no FDA approved treatments for AL amyloidosis; regimens developed for multiple myeloma are used off-label to treat the plasma cell disorder and no therapies are directed at organ deposition. Thus, an unmet medical need persists despite advances in disease management. A public-private partnership was recently formed between the Amyloidosis Research Consortium (ARC) and the US Food and Drug Administration (FDA) to bridge scientific gaps in drug development for the treatment of AL amyloidosis.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Main Body<\/jats:title>\n<jats:p>The inaugural Amyloidosis Forum was convened at FDA on 12 November 2019 and led by a multidisciplinary panel of physicians, health outcomes professionals, and representatives from the FDA, ARC, and pharmaceutical companies. Patients provided important perspectives on the pathway to diagnosis, challenges of rigorous treatment, and the burden of disease. The panel reviewed the epidemiology, pathobiology, and clinical features of AL amyloidosis. Hematologic characteristics, staging systems, and response criteria were examined with clear consensus that a \u201cdeep response\u201d to plasma cell-directed treatments was critical to overall survival. Emphasis was placed on the heterogeneous clinical phenotypes of AL amyloidosis, including cardiovascular, renal, neurological, and gastrointestinal system manifestations that contribute to morbidity and\/or mortality, but render challenges to clinical trial endpoint selection. FDA representatives discussed regulatory perspectives regarding demonstration of clinical benefits of investigational therapies in the context of a rare disease with multi-systemic manifestations. The panel also highlighted the potential importance of well-designed health-related quality of life instruments, quantification of system organ effects, the potential of advanced imaging technologies, and survival prediction models.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The Amyloidosis Forum identified a clear need for novel trial designs that are scientifically rigorous, feasible, and incorporate clinically meaningful endpoints based on an understanding of the natural history of the disease in an evolving therapeutic landscape. Future forums will delve into these issues and seek to include participation from additional stakeholders.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13023-020-01525-2","type":"journal-article","created":{"date-parts":[[2020,9,29]],"date-time":"2020-09-29T11:03:09Z","timestamp":1601377389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis"],"prefix":"10.1186","volume":"15","author":[{"name":"The Inaugural Amyloidosis Forum Panelists","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John O.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Comenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Dember","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preston","family":"Dunnmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas V.","family":"Faller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney H.","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Gormley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol D.","family":"Karp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Landau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica L.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Lousada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle L.","family":"Mauermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathew","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishali","family":"Sanchorawala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Signorovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh D.","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brendan M.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle K.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2944-1673","authenticated-orcid":false,"given":"Isabelle","family":"Lousada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,29]]},"reference":[{"issue":"1","key":"1525_CR1","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1586\/17474086.2014.858594","volume":"7","author":"G Merlini","year":"2014","unstructured":"Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Immunoglobulin light chain amyloidosis. Expert Rev Hematol. 2014;7(1):143\u201356.","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"1525_CR2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.mayocp.2019.01.023","volume":"94","author":"RA Kyle","year":"2019","unstructured":"Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, et al. Incidence of AL amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Mayo Clin Proc. 2019;94(3):465\u201371.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"1525_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","volume":"4","author":"G Merlini","year":"2018","unstructured":"Merlini G, Dispenzieri A, Sanchorawala V, Schonland SO, Palladini G, Hawkins PN, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"1525_CR4","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1007\/s12325-015-0250-0","volume":"32","author":"I Lousada","year":"2015","unstructured":"Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015;32(10):920\u20138.","journal-title":"Adv Ther"},{"issue":"3","key":"1525_CR5","first-page":"472","volume":"94","author":"E Muchtar","year":"2019","unstructured":"Muchtar E, Gertz MA, Kyle RA, Lacy MQ, Dingli D, Leung N, et al. A modern primer on light chain amyloidosis in 592 patients with mass spectrometry-verified typing. Mayo Clin Proc. 2019;94(3):472\u201383.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"1525_CR6","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1182\/blood-2006-03-001164","volume":"108","author":"G Merlini","year":"2006","unstructured":"Merlini G, Stone MJ. Dangerous small B-cell clones. Blood. 2006;108(8):2520\u201330.","journal-title":"Blood"},{"issue":"24","key":"1525_CR7","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1182\/blood-2015-10-673095","volume":"127","author":"B Paiva","year":"2016","unstructured":"Paiva B, Martinez-Lopez J, Corchete LA, Sanchez-Vega B, Rapado I, Puig N, et al. Phenotypic, transcriptomic, and genomic features of clonal plasma cells in light-chain amyloidosis. Blood. 2016;127(24):3035\u20139.","journal-title":"Blood"},{"issue":"10","key":"1525_CR8","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.3324\/haematol.2017.171108","volume":"102","author":"I Meziane","year":"2017","unstructured":"Meziane I, Huhn S, Filho M, Weinhold N, Campo C, Nickel J, et al. Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts. Haematologica. 2017;102(10):e411\u2013e4.","journal-title":"Haematologica"},{"issue":"7","key":"1525_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1182\/bloodadvances.2018016782","volume":"2","author":"MH Sidiqi","year":"2018","unstructured":"Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, et al. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Adv. 2018;2(7):769\u201376.","journal-title":"Blood Adv"},{"issue":"3","key":"1525_CR10","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/leu.2017.286","volume":"32","author":"S Sidana","year":"2018","unstructured":"Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, et al. Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains. Leukemia. 2018;32(3):729\u201335.","journal-title":"Leukemia"},{"key":"1525_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1750-1172-7-54","volume":"7","author":"E Desport","year":"2012","unstructured":"Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, et al. Al amyloidosis. Orphanet J Rare Dis. 2012;7:54.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"1525_CR12","first-page":"315","volume":"13","author":"CP Chaulagain","year":"2015","unstructured":"Chaulagain CP, Comenzo RL. How we treat systemic light-chain amyloidosis. Clin Adv Hematol Oncol. 2015;13(5):315\u201324.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"1","key":"1525_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1182\/blood.V68.1.220.220","volume":"68","author":"RA Kyle","year":"1986","unstructured":"Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 1986;68(1):220\u20134.","journal-title":"Blood"},{"issue":"9","key":"1525_CR14","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989\u201395.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1525_CR15","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/blood-2005-07-2922","volume":"107","author":"A Dispenzieri","year":"2006","unstructured":"Dispenzieri A, Lacy MQ, Katzmann JA, Rajkumar SV, Abraham RS, Hayman SR, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006;107(8):3378\u201383.","journal-title":"Blood"},{"issue":"5","key":"1525_CR16","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","volume":"130","author":"T Dittrich","year":"2017","unstructured":"Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood. 2017;130(5):632\u201342.","journal-title":"Blood"},{"issue":"5","key":"1525_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","volume":"130","author":"P Milani","year":"2017","unstructured":"Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130(5):625\u201331.","journal-title":"Blood"},{"issue":"1","key":"1525_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/ajh.24919","volume":"93","author":"N Tandon","year":"2018","unstructured":"Tandon N, Sidana S, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, et al. Impact of involved free light chain (FLC) levels in patients achieving normal FLC ratio after initial therapy in light chain amyloidosis (AL). Am J Hematol. 2018;93(1):17\u201322.","journal-title":"Am J Hematol"},{"issue":"25","key":"1525_CR19","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019000834","volume":"134","author":"R Manwani","year":"2019","unstructured":"Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134(25):2271\u201380.","journal-title":"Blood"},{"issue":"2","key":"1525_CR20","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","volume":"128","author":"G Palladini","year":"2016","unstructured":"Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128(2):159\u201368.","journal-title":"Blood"},{"issue":"15","key":"1525_CR21","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK, et al. Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood. 2017;129(15):2111\u20139.","journal-title":"Blood"},{"issue":"5","key":"1525_CR22","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/s41408-018-0086-3","volume":"8","author":"E Kastritis","year":"2018","unstructured":"Kastritis E, Kostopoulos IV, Terpos E, Paiva B, Fotiou D, Gavriatopoulou M, et al. Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis. Blood Cancer J. 2018;8(5):46.","journal-title":"Blood Cancer J"},{"issue":"11","key":"1525_CR23","doi-asserted-by":"publisher","first-page":"2360","DOI":"10.1016\/j.bbmt.2018.06.027","volume":"24","author":"MH Sidiqi","year":"2018","unstructured":"Sidiqi MH, Aljama MA, Jevremovic D, Muchtar E, Buadi FK, Warsame R, et al. Prognostic significance of stringent complete response after stem cell transplantation in immunoglobulin light chain amyloidosis. Biol Blood Marrow Transplant. 2018;24(11):2360\u20134.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"1525_CR24","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","volume":"36","author":"MH Sidiqi","year":"2018","unstructured":"Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J Clin Oncol. 2018;36(13):1323\u20139.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1525_CR25","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41409-018-0284-4","volume":"54","author":"C Varga","year":"2019","unstructured":"Varga C, Comenzo RL. High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. Bone Marrow Transplant. 2019;54(4):508\u201318.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"1525_CR26","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3324\/haematol.2014.104109","volume":"99","author":"A Jaccard","year":"2014","unstructured":"Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naive patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014;99(9):1479\u201385.","journal-title":"Haematologica"},{"issue":"15","key":"1525_CR27","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325\u201332.","journal-title":"Blood"},{"issue":"3","key":"1525_CR28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ajh.23898","volume":"90","author":"GP Kaufman","year":"2015","unstructured":"Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol. 2015;90(3):181\u20136.","journal-title":"Am J Hematol"},{"issue":"2","key":"1525_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s40271-017-0273-5","volume":"11","author":"KL McCausland","year":"2018","unstructured":"McCausland KL, White MK, Guthrie SD, Quock T, Finkel M, Lousada I, et al. Light chain (AL) amyloidosis: the journey to diagnosis. Patient. 2018;11(2):207\u201316.","journal-title":"Patient"},{"issue":"4","key":"1525_CR30","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/13506129.2015.1102131","volume":"22","author":"HM Lin","year":"2015","unstructured":"Lin HM, Seldin D, Hui AM, Berg D, Dietrich CN, Flood E. The patient's perspective on the symptom and everyday life impact of AL amyloidosis. Amyloid. 2015;22(4):244\u201351.","journal-title":"Amyloid"},{"key":"1525_CR31","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/1477-7525-10-154","volume":"10","author":"M Bayliss","year":"2012","unstructured":"Bayliss M, Rendas-Baum R, White MK, Maruish M, Bjorner J, Tunis SL. Health-related quality of life (HRQL) for individuals with self-reported chronic physical and\/or mental health conditions: panel survey of an adult sample in the United States. Health Qual Life Outcomes. 2012;10:154.","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"1525_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","volume":"273","author":"IB Wilson","year":"1995","unstructured":"Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. JAMA. 1995;273(1):59\u201365.","journal-title":"JAMA"},{"key":"1525_CR33","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2147\/PROM.S146849","volume":"8","author":"MK White","year":"2017","unstructured":"White MK, McCausland KL, Sanchorawala V, Guthrie SD, Bayliss MS. Psychometric validation of the SF-36 health survey in light chain amyloidosis: results from community-based and clinic-based samples. Patient Relat Outcome Meas. 2017;8:157\u201367.","journal-title":"Patient Relat Outcome Meas"},{"issue":"6","key":"1525_CR34","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1182\/blood-2004-01-0089","volume":"104","author":"DC Seldin","year":"2004","unstructured":"Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 2004;104(6):1888\u201393.","journal-title":"Blood"},{"issue":"3","key":"1525_CR35","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1111\/bjh.14889","volume":"179","author":"V Sanchorawala","year":"2017","unstructured":"Sanchorawala V, McCausland KL, White MK, Bayliss MS, Guthrie SD, Lo S, et al. A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time. Br J Haematol. 2017;179(3):461\u201370.","journal-title":"Br J Haematol"},{"key":"1525_CR36","doi-asserted-by":"crossref","unstructured":"Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, et al. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016;30(10):1979\u201386.","DOI":"10.1038\/leu.2016.191"},{"issue":"36","key":"1525_CR37","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541\u20139.","journal-title":"J Clin Oncol"},{"issue":"14","key":"1525_CR38","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1161\/CIRCULATIONAHA.116.024438","volume":"135","author":"MS Maurer","year":"2017","unstructured":"Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017;135(14):1357\u201377.","journal-title":"Circulation"},{"issue":"4","key":"1525_CR39","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.3324\/haematol.2017.178095","volume":"103","author":"R Manwani","year":"2018","unstructured":"Manwani R, Foard D, Mahmood S, Sachchithanantham S, Lane T, Quarta C, et al. Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis. Haematologica. 2018;103(4):e165\u2013e8.","journal-title":"Haematologica"},{"issue":"4","key":"1525_CR40","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th international symposium on amyloid and amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005;79(4):319\u201328.","journal-title":"Am J Hematol"},{"issue":"2","key":"1525_CR41","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1182\/bloodadvances.2018021253","volume":"3","author":"G Palladini","year":"2019","unstructured":"Palladini G, Merlini G. When should treatment of AL amyloidosis start at relapse? Early, to prevent organ progression. Blood Adv. 2019;3(2):212\u20135.","journal-title":"Blood Adv"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01525-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01525-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01525-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,28]],"date-time":"2021-09-28T23:33:58Z","timestamp":1632872038000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01525-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,29]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1525"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01525-2","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,29]]},"assertion":[{"value":"1 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"268"}}